Dr. Pervez Ahmed Siddiqui, S07209
This study was conducted during a duration of two years in all 100 patients were enrolled during this study All patients after duly obtaining the requisite were administered 0.5 mg of ranibizumab intra vitreally.Necessary topical antibiotics and pressure lowering agents were duly prescribed.Monthly injections were given for three months on monthly basis followed by as and when required if more than 1O0 mu
micron increse in central fovea thickness or loss of 15 letters occured after three injectionsCommon complications were heaviness at the site of injections 78%,visualising single or multiples bubbles in eyes 75%and endophthalmitis in 1%Results Visual improvement of three lines occured in 84% patients sustainable in 63% patients during two years duration ,with commiserate reduction in cft measured by spectral domain Oct Patients were regularly followed up for two years duration and present will discuss every aspect in detail